CRL

188.68

3.40% 6.20

Dopo l'orario di chiusura: 188.68

Charles River Laboratories International Inc (CRL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$182.48

Aprire:

$180.89

Volume 24 ore:

990.33K

Relative Volume:

1.34

Capitalizzazione di mercato:

$10.63B

Reddito:

$4.08B

Utile/perdita netta:

$431.79M

Rapporto P/E:

20.01

EPS:

9.43

Flusso di cassa netto:

$486.92M

1 W Prestazione:

+2.54%

1M Prestazione:

-1.08%

6M Prestazione:

-19.18%

1 anno Prestazione:

+3.72%

Intervallo 1D:

$180.50

$189.18

Intervallo di 1 settimana:

$176.48

$189.18

Portata 52W:

$166.87

$275.00

Charles River Laboratories International Inc Stock (CRL) Company Profile

Nome

Charles River Laboratories International Inc

Settore

Healthcare (1182)

Industria

Diagnostics & Research (57)

Telefono

781-222-6000

Indirizzo

251 BALLARDVALE ST, WILMINGTON, MA

Dipendente

Cinguettio

@criverlabs

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

CRL's Discussions on Twitter

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-15	Downgrade	Guggenheim	Buy → Neutral
2023-09-13	Iniziato	TD Cowen	Market Perform
2023-07-10	Downgrade	Citigroup	Buy → Neutral
2023-02-23	Aggiornamento	Guggenheim	Neutral → Buy
2023-01-12	Downgrade	Jefferies	Buy → Hold
2022-09-30	Aggiornamento	Jefferies	Hold → Buy
2022-08-25	Iniziato	Credit Suisse	Outperform
2022-08-04	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-05-24	Iniziato	Guggenheim	Neutral
2022-04-25	Downgrade	Jefferies	Buy → Hold
2022-04-07	Iniziato	Stephens	Overweight
2022-02-17	Reiterato	BofA Securities	Buy
2022-02-17	Aggiornamento	Citigroup	Neutral → Buy
2022-02-17	Reiterato	Deutsche Bank	Buy
2022-02-17	Reiterato	Morgan Stanley	Overweight
2022-02-17	Reiterato	UBS	Buy
2021-08-05	Ripresa	Credit Suisse	Neutral
2020-12-16	Downgrade	Citigroup	Buy → Neutral
2020-09-10	Aggiornamento	Jefferies	Hold → Buy
2020-07-01	Aggiornamento	BofA Securities	Neutral → Buy
2020-05-13	Aggiornamento	UBS	Neutral → Buy
2020-04-21	Downgrade	Jefferies	Buy → Hold
2020-03-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-03-02	Iniziato	Deutsche Bank	Buy
2020-02-18	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2020-01-10	Aggiornamento	Goldman	Neutral → Buy
2020-01-08	Iniziato	Wells Fargo	Overweight
2020-01-07	Iniziato	Citigroup	Buy
2019-10-18	Downgrade	BofA/Merrill	Buy → Neutral
2019-06-10	Iniziato	SVB Leerink	Outperform
2019-04-30	Ripresa	Evercore ISI	Outperform
2018-12-14	Iniziato	Deutsche Bank	Buy
2018-10-09	Iniziato	UBS	Neutral
2018-08-23	Aggiornamento	Raymond James	Mkt Perform → Outperform
2018-07-17	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2018-06-15	Aggiornamento	KeyBanc Capital Mkts	Sector Weight → Overweight
2018-02-14	Aggiornamento	SunTrust	Hold → Buy

Mostra tutto

Charles River Laboratories International Inc Borsa (CRL) Ultime notizie

11:37 AM

Charles River Laboratories Q3 2024 Earnings Preview - MSN

11:37 AM

04:13 AM

Stephens Inc. AR Raises Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

04:13 AM

03:55 AM

Cell Banking Outsourcing Market Report: Detailed Insights - openPR

03:55 AM

Nov 04, 2024

Gear Up for Charles River (CRL) Q3 Earnings: Wall Street Estimates for Key Metrics - Yahoo Finance

Nov 04, 2024

abrdn plc Decreases Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

Nov 04, 2024

Gmp Cell Banking Services Market Size, Share, and Forecast - openPR

Nov 04, 2024

Nov 03, 2024

Restructuring update likely in Charles River Labs’ Q3 earnings - The Business Journals

Nov 03, 2024

Nov 01, 2024

Charles River Laboratories International, Inc. (NYSE:CRL) Short Interest Update - MarketBeat

Nov 01, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Nov 01, 2024

Oct 31, 2024

Zacks Research Has Weak Forecast for CRL FY2024 Earnings - MarketBeat

Oct 31, 2024

Congress Asset Management Co. Sells 9,239 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

Oct 31, 2024

Oct 30, 2024

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Oct 30, 2024

WD Rutherford LLC Has $338,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

Oct 30, 2024

Charles River Laboratories International (CRL) to Release Earnings on Wednesday - MarketBeat

Oct 30, 2024

Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Rating of "Reduce" by Analysts - MarketBeat

Oct 30, 2024

Oct 29, 2024

Fragment Based Drug Discovery Market Size Projected to Achieve USD 2.1 Billion by 2031, Expanding at a 11.5% CAGR | Analysis by Transparency Market Research, Inc. - GlobeNewswire Inc.

Oct 29, 2024

Why Charles River (CRL) is Poised to Beat Earnings Estimates Again - Zacks Investment Research

Oct 29, 2024

Oct 28, 2024

Assenagon Asset Management S.A. Acquires 29,621 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

Oct 28, 2024

Oct 27, 2024

Ophthalmic Clinical Trials Market Intelligence Reports - openPR

Oct 27, 2024

Boston Trust Walden Corp Decreases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

Oct 27, 2024

Oct 26, 2024

Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet - Simply Wall St

Oct 26, 2024

Oct 25, 2024

Dumont & Blake Investment Advisors LLC Sells 4,360 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

Oct 25, 2024

Oct 23, 2024

CLSA Begins Coverage on Charles River Laboratories International (NYSE:CRL) - MarketBeat

Oct 23, 2024

Oct 22, 2024

Charles River Laboratories International (NYSE:CRL) Trading Down 4.9%Should You Sell? - MarketBeat

Oct 22, 2024